OIE RL for « Equine Viral Arteritis » – « Peter Timoney » – « United States of America »
OIE Reference Laboratory Reports
Activities in 2012
Address of laboratory / Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY 40546
Tel.: / +1-859-218-1094
Fax: / +1-859-257-8542
e-mail address: /
website: / --
Name (including Title) of Head of Laboratory (Responsible Official): / Dr. Mats Troedsson, Director
Maxwell H. Gluck Equine Research Center
Name (including Title and Position) of OIE Reference Expert: / Dr.Peter Timoney, Professor
Frederick Van Lennep Chair in Equine Veterinary Science
Date of submission to the OIE / 01/25/13
Instructions
This form should be used by an OIE Reference Laboratory to report activities that took place from January through December of the past year (2012), unless otherwise stated, and must be submitted by the end of January every year.
Only those activities that concern the disease (or topic) for which the laboratory is recognised by the OIE should be mentioned. The questionnaire structure follows the Terms of Reference (ToRs) for OIE Reference Laboratories, available at:
EachToR(blueitalicised text)has been placed as a heading covering the group of questions related to it.
Please note the reditalicisedtext is given as guidance and should be deleted from your report and substitute with your data. Examples are based onpast Annual Reports or have been invented.
The questionnaire represents a means of gathering information on activities carried out by OIE Reference Laboratories and making it available to OIE Member Countries and to the OIE Reference Laboratory network.
This annual report will remain available for consultation on the OIE web site:
(
ToR:To use, promote and disseminate diagnostic methods validated according to OIE Standards
Test recommended by the OIE / Total number of test performed last yearIndirect diagnostic tests / Nationally / Internationally
VN / 12,460 / 130
Direct diagnostic tests / Nationally / Internationally
Virus isolation (RK-13 & equine endothelial cells)
/ 322 / 24Real-time RT-PCR
/ 10 / --FAT
/ 4 / --ToR:To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
Tostore and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.
2.Did your laboratory produce or store imported standard reference reagentsofficially recognised by the OIE or other international bodies?
Yes No
3.Did your laboratory supply standard reference reagentsto OIE Member Countries?
Yes No
Type of reagent available / Related diagnostic test / Produced/stored / Amount supplied nationally
(ml, mg) / Amount supplied internationally
(ml, mg) / Name of recipient OIE Member Countries and of institutions
Control positive sera (OIE-approved) / VN / Produced / -- / 4.5 ml / S. Africa, ARC-OVI, Onderstepoort
Control negative sera (OIE-approved) / VN / Produced / -- / 1.5 ml / S. Africa, ARC-OVI, Onderstepoort
Control positive serum panel / VN / Produced / -- / 8 ml / S. Africa, ARC-OVI, Onderstepoort
Control positive serum panel / VN / Produced / 97 ml / -- / USA, Gluck Equine Research Center
Control negative serum panel / VN / Produced / -- / 2 ml / S. Africa, ARC-OVI, Onderstepoort
Control negative serum panel / VN / Produced / -- / 31 ml / USA, Gluck Equine Research Center
RK-13 & EEC cell lines / VN/VI / Produced / -- / 1x75 cm2 flask / S. Africa, ARC-OVI, Onderstepoort
RK-13 & EEC cell lines / VN/VI / Produced / -- / 2x75 cm2 flask / Italy, IstitutoZooprofilattico, LatioTuscany, Rome
RK-13 & EEC cell lines / VN/VI / Produced / -- / 7,106x25 cm2 flasks (RK-13) / USA, Gluck Equine Research Center
RK-13 & EEC cell lines / VN/VI / Produced / -- / 346x25 cm2 flasks (EEC) / USA, Gluck Equine Research Center
4.Did your laboratory produce diagnostic reagents other than the OIE-approved standard reference reagents?
Yes No
5.Did your laboratory produce vaccines?
Yes No
6.Did your laboratory supply vaccines to OIE Member Countries?
Yes No
ToR:To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases
7.Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?
Yes No
8.Didyour laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?
Yes No
ToR:To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries
9.Did your laboratory carry out diagnostic testing for other OIE Member Countries?
Yes No
Name of OIE Member Country seeking assistance / Date(dd/mm) / No. samples received for provision of diagnostic support (i.e. from surveillance campaign) / No. samples received for provision of confirmatory diagnoses
Colombia / 1 May / -- / 3
Netherlands / 19 May / 1 / --
Colombia / 8 February / -- / 1
Germany / 20 February / 16 / --
Canada / 27 February / 1 / --
Colombia / 9 March / -- / 1
Germany / 16 March / 19 / --
Canada / 2 April / 4 / --
Germany / 3 April / 4 / --
Netherlands / 19 April / 1 / --
Colombia / 1 June / -- / 4
Canada / 5 June / 6 / --
Canada / 7 June / 2 / --
Canada / 14 June / 1 / --
Germany / 13 July / 21 / --
Canada / 14 August / 1 / --
Germany / 15 August / 9 / --
United Kingdom / 13 September / -- / 1
Antigua / 23 October / 9 / --
Denmark / 2 November / 1 / --
Netherlands / 2 November / 1 / --
Netherlands / 26 November / 22 / --
Netherlands / 29 November / 1 / --
Netherlands / 19 January / 1 / --
Germany / 4 April / -- / 1
Netherlands / 19 April / 1 / --
Canada / 5 June / 16 / --
Canada / 3 July / 2 / --
Canada / 14 August / 2 / --
Canada / 21 August / 1 / --
10.Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?
Yes No
Name of the OIE Member Country receiving a technical consultancy / Purpose / How the advice was providedMozambique / Resolve problem over horse movement from S. Africa to Mozambique / Remote assistance (e-mail)
Russia / Participation in int’l horse breeding conference in Novosibirsk / Remote assistance (e-mail)
USA / Clarify whether transmission of EAV occurs by embryo transfer / Remote assistance (e-mail)
USA / Proposed amendments to Code Chapter on EVA / Remote assistance (e-mail)
Uruguay / Proposed twinning of labs / Remote assistance (e-mail)
Colombia / Resolution of problem over VN test interpretation / Remote assistance (e-mail)
United Kingdom / Provision of illustrations of EVA / Remote assistance (e-mail)
Germany / Evaluation of in vitro characteristics of EAV strains from carrier stallion / Remote assistance (e-mail)
Australia / Participant in Horse Import Risk Analysis Review / Remote assistance (e-mail)
Australia / Clarification over test procedures for EAV detection in semen / Remote assistance (e-mail)
Chile / Resolution of queries over import requirements for stallions and semen / Remote assistance (e-mail)
Brazil / Resolution of problem over reagents used in EAV VN test / Remote assistance (e-mail)
Turkey / Technical queries over EVA ELISA / Remote assistance (e-mail)
Italy / Technical queries over sensitivity of RK-13 cell lines for EAV isolation / Remote assistance (e-mail)
S. Africa / Technical queries over OIE approved tests for diagnosis of EVA / Remote assistance (e-mail)
PR China / Queries over personnel training in tests for diagnosis of EVA / Remote assistance (e-mail)
Australia / Queries over technical problems in testing stallion for carrier state / Remote assistance (e-mail)
Antigua / Investigation of EVA-like syndrome in imported horses / Remote assistance (e-mail)
ToR:To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations
11.Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than your own?
Yes No
Title of the study / Duration / Purpose of the study / Partners (Institutions) / OIE Member Countries involved other than your countryEffect of Single Layer Centrifugation on reduction of EAV in Semen from Carrier Stallions / 1-2 years / Develop method of removing EAV from infective semen / University of Agriculture Sciences, Uppsala, Sweden / Sweden
Improved Methods for Detection of EAV in Semen / 2+ years / Development of improved virus detection tests for EAV / Frank Duncombe Laboratory, Caen, France / France
Factors Impeding Isolation of EAV from Semen / 1-2 years / Refinement of current VI techniques for EAV / Central Veterinary Laboratory, New Haw, Weybridge, UK / United Kingdom
ToR:To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases
12.Didyour Laboratory collect epizootiologicaldata relevant to international disease control?
Yes No
13.Didyour laboratory disseminate epizootiologicaldata that had been processed and analysed?
Yes No
14.What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)
a)Articles published in peer-reviewed journals:...... 4
b)International conferences:...... 2
c)National conferences:...... 2
d)Other:...... 1 chapter
ToR: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards
15.Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?
Yes No
a)Technical visits:...... 2
b)Seminars:...... 0
c)Hands-on training courses:...... 0
d)Internships (>1 month):...... 0
Type of technical training provided (a, b,c or d) / Country of origin of the expert(s) provided with training / No. participants from the corresponding countrya / Turkey / 1
a / Brazil / 1
ToR:To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned
16.Does your laboratory have a Quality Management System certified according to an International Standard?
Yes No
17.Is your laboratory accredited by an international accreditation body?
Yes No
18.Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned? (See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2012, Chapter 1.1.3 orManual of Diagnostic Tests for Aquatic Animals 2012, Chapter 1.1.1)
Yes No
ToR:To organise and participate in scientific meetings on behalf of the OIE
19.Did your laboratory organise scientific meetings on behalf of the OIE?
Yes No
20.Did your laboratory participate in scientific meetings on behalf of the OIE?
Yes No
Title of event / Date(mm/yy) / Location / Role (speaker, presenting poster, short communications) / Title of the work presented
Brainstorming Meeting on International Movement of Horses / 03/12 / OIE, Paris / Speaker / Impediments to Greater Facilitation of International Movement of Equids
OIE Regional Workshop on Facilitation of International Competition Horse Movement / 12/12 / Panama / Resource person / N/A
ToR:To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results
21.Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?
Yes No
22.Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?
Yes No
23.Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?
Yes No
Title of the project or contact / Scope / Name(s) of relevant OIE Reference LaboratoriesFactors Impeding Isolation of EAV from Semen / Refinement of current VI techniques for EAV / Central Veterinary Laboratory, New Haw, Weybridge, United Kingdom
ToR:To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results.
24.Did your laboratory organiseor participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?
Yes No
Purpose for inter-laboratory test comparisons1 / No. participating laboratories / Participating OIE Member CountriesHarmonise VN test virus detection (VI & RT-PCR tests) / 2 / Canada, S. Africa
Evaluate new serologic test method / 1 / USA
ToR:To place expert consultants at the disposal of the OIE
25.Did your laboratory place expert consultants at the disposal of the OIE?
Yes No
Kind of consultancy / Location / Subject (facultative)ad hoc Group / Paris (OIE) / Brainstorming Meeting on International Movement of Horses
Resource person / Panama / OIE Regional Workshop on International Movement of Performance Horses
Provision of comments on OIE Standards / Remote assistance (e-mail) / Contributed to revision of Chapter 2.5.10 OIE Manual Diagnostic Tests & Vaccines
Provision of comments on OIE Standards / Remote assistance (e-mail) / Proposed revisions to Chapter 12.9 OIE Animal Health Code
2012 EVA References
1) Go YY, Cook RF, Fulgencio JQ, Campos JR, Henney P, TimoneyPJ and Balasuriya UBR (2012) Assessment of Correlation between In Vitro CD3+ T Cell Susceptibility to EAV Infection and Clinical Outcome Following Experimental Infection. Vet Micro, 157:220-225.
2) Lu Z, Zhang J, Huang CM, Go YY, Faaberg KS, Rowland R, Timoney PJ and Balasuriya UBR (2012) Chimeric viruses containing the N-terminal ectodomains of GP5 and M proteins of porcine reproductive and respiratory syndrome virus do not change the cellular tropism of equine arteritis virus, Virology, 432:99-109.
3) Go YY, Bailey E, Timoney P, Shuck K and BalasuriyaUBR (2012) Evidence for genetic predisposition of naturally infected stallions to become carriers of equine arteritis virus, J Virol, 86:12407-12410.
4) Zhang J, Go YY, Huang C, Meade B, Lu Z, Snijder E, Timoney P and Balasuriya UBR (2012) Development and characterization of an infectious cDNA clone of the modified live virus vaccine strain of equine arteritis virus, Clin Vaccine Immunol, 19:1312-1321.
5) TimoneyPJ (2012) Equine Viral Arteritis. In OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, 7th Edition, Office International des Epizooties, Paris, pp. 899-912.
See Interlaboratory test comparisons in: Laboratory Proficiency Testing at:
see point 1.3
Annual reports of OIE Reference Laboratories, 20121